FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Ashkan M. Abbey, MD, shares topline data from the phase 2 DAVIO 2 trial investigating Duravyu for wet age-related macular degeneration.
The study met its primary endpoint of noninferiority to the standard of care in best corrected visual acuity at week 32 in patients who received Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals). Abbey also discussed the treatment burden and safety results.
“We’re looking at potential for a new therapy that allows us to treat and maintain